Nephrol Dial Transplant (2001) 16: 2158-2165
© 2001 European Renal Association-European Dialysis and Transplant Association
The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study
1 Mattias Aurell and Hans Herlitz, Department of Nephrology, Sahlgrenska Hospital, Göteborg University, Sweden, 2 Kevin Harris, Department of Nephrology, Leicester General Hospital, University of Leicester, UK, 3 Teut Risler, Sektion Nieren- und Hochdruckkrankheiten, Universitätsklinikum Tübingen, Germany, 4 Geoffrey Boner, Institute of Hypertension and Kidney Diseases, Rabin Medical Center, Tel-Aviv University, Israel, 5 Jacques Bernheim, Department of Nephrology and Hypertension, Meir General Hospital, Sapir Medical Center, Israel and 6 Jacques Chanard, Service de Nephrologie, Dialyse, Hypertension et Transplantation Rénale, Reims, France
Background. The renoprotective effect of ACE inhibition in chronic renal disease is well established but the studies on effects of calcium antagonists on progression of renal disease and on proteinuria have given varying results.
Methods. We conducted an open long-term randomized prospective multi-centre study comparing the combination of ramipril (R) and felodipine ER (F) with either drug alone in non-diabetic renal disease. Included were patients with uncontrolled hypertension (diastolic blood pressure (DBP)) 
95 mmHg on treatment with a diuretic and a beta-blocker. Fifty-one patients received the combination of R and F, 54 patients R, and 53 patients F. The treatment goal was a DBP <90 mmHg and a similar BP reduction in the three groups. Mean doses at the last visit were 5+5, 10 and 9 mg, respectively, after a mean treatment time of nearly 2 years. The progression of renal impairment was studied by serial measurements of serum creatinine, iohexol clearance, and albuminuria.
Results. The reduction in supine systolic (S) BP and DBP expressed as median values were -19.0/-14.5,-14.3/-15.0 and -13.5/-13.3 mmHg in the R+F, R, and F groups, respectively. There was no significant difference between the groups. When correction for the acute drug effect was performed the R+F group had a slower progression rate of the renal disease (loss of glomerular filtration rate (GFR) ml/min/year) compared with the F group (P<0.05) but not to the R group (P>0.20). There was a rise in albuminuria after 2 years in the F group (P<0.05), but no significant change was found in the other groups.
Conclusions. In patients with non-diabetic renal disease the combination of an ACE inhibitor and a calcium antagonist in reduced doses used in addition to baseline therapy with beta-blockers and diuretics, tended to cause a better BP reduction as each drug per se. The R+F treatment also caused a slower progression of the renal disease compared with F alone. The combination treatment seems to afford better BP control and appears to be a favourable therapeutic option in patients with renal disease and hypertension.
Keywords: ACE inhibitor; albuminuria; calcium antagonist; hypertension; progression; renal disease
Correspondence and offprint requests to: Hans Herlitz, Department of Nephrology, Sahlgrenska University Hospital, SE-413 45 Göteborg, Sweden. Email: hans.herlitz{at}medic.gu.se
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Remuzzi, M. Macia, and P. Ruggenenti Prevention and Treatment of Diabetic Renal Disease in Type 2 Diabetes: The BENEDICT Study J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S90 - S97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Abbott, E. Basta, and G. L. Bakris Blood Pressure Control and Nephroprotection in Diabetes J. Clin. Pharmacol., April 1, 2004; 44(4): 431 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Bakris, M. R. Weir, S. Shanifar, Z. Zhang, J. Douglas, D. J. van Dijk, and B. M. Brenner Effects of Blood Pressure Level on Progression of Diabetic Nephropathy: Results From the RENAAL Study Arch Intern Med, July 14, 2003; 163(13): 1555 - 1565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Swales and B. Williams Review: Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT1-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension Journal of Renin-Angiotensin-Aldosterone System, June 1, 2002; 3(2): 79 - 89. [Abstract] [PDF]
|
|